TRIAL DETAIL
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 06/21/2011 |
Age of Trial (yrs) 13.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
Immune stimulate |
|||
Strategy: |
Stimulate the immune system |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
OSU-09138, NCI-2011-00920 |
|||
Sponsor: |
Ohio State University Comprehensive Cancer Center. Robert Wesolowski |
|||
Patient Contact: |
Pravin T.P Kaumaya, PhD
614-292-7028
pravin.kaumaya@osumc.edu |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells. |
|||
Trial Links |
Trial Results |
Drug Information |
| Hum Vaccin Immunother. 2015;11(6):1368-86. doi: 10.1080/21645515.2015.1026495. |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Columbus |
OH |
43210 |
USA |